Ignite Creation Date:
2025-12-24 @ 7:32 PM
Ignite Modification Date:
2025-12-29 @ 10:17 AM
Study NCT ID:
NCT05582603
Status:
UNKNOWN
Last Update Posted:
2022-10-18
First Post:
2022-10-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000094024', 'term': 'Post-Acute COVID-19 Syndrome'}, {'id': 'D060825', 'term': 'Cognitive Dysfunction'}], 'ancestors': [{'id': 'D000086382', 'term': 'COVID-19'}, {'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D000094025', 'term': 'Post-Infectious Disorders'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D003072', 'term': 'Cognition Disorders'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Phase I: An open-label prospective Phase I dose-escalation study following a standard 3+3 rule-based up-and-down design without dose de-escalation will be followed.\n\nPhase II: An open-label prospective clinical trial to validate the minimum dosage and appropriate safety using the training time obtained in Phase I for the CCT along a 15-day training period with a 24-hour rest between sessions.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 20}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2022-10-18', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-10', 'completionDateStruct': {'date': '2022-11-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2022-10-16', 'studyFirstSubmitDate': '2022-10-13', 'studyFirstSubmitQcDate': '2022-10-13', 'lastUpdatePostDateStruct': {'date': '2022-10-18', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-10-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-11-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Fatigue Level Questionnaire', 'timeFrame': 'In Phase I, after each iteration of a 15-minute training.', 'description': 'Fatigue questionnaire adapted from the Brief Fatigue Inventory (Mendoza et al., 1999)'}, {'measure': 'Fatigue Level Questionnaire', 'timeFrame': 'In Phase II, on even days (rest days of the intervention protocol).', 'description': 'Fatigue questionnaire adapted from the Brief Fatigue Inventory (Mendoza et al., 1999)'}, {'measure': 'Safety Level Questionnaire', 'timeFrame': 'In Phase I, after each iteration of a 15-minute training.', 'description': 'Safety questionnaire aimed at exploring the existence of side effects and/or adverse events.'}, {'measure': 'Safety Level Questionnaire', 'timeFrame': 'In Phase II, on even days (rest days of the intervention protocol).', 'description': 'Safety questionnaire aimed at exploring the existence of side effects and/or adverse events.'}, {'measure': 'Classification of side effect or adverse events', 'timeFrame': 'In Phase I, after each iteration of a 15-minute training, only in case side effects or adverse events have been reported in the Safety Questionnaire.', 'description': 'Interview adapted from the Patient-Reported Adverse Drug Event Questionnaire (de Vries et al., 2013).'}, {'measure': 'Classification of side effect or adverse events', 'timeFrame': 'In Phase II, on even days (rest days of the intervention protocol), only in case side effects or adverse events have been reported in the Safety Questionnaire.', 'description': 'Interview adapted from the Patient-Reported Adverse Drug Event Questionnaire (de Vries et al., 2013).'}], 'secondaryOutcomes': [{'measure': 'Computerized Cognitive Assessment', 'timeFrame': 'In Phase II, at pre-test (the day before the intervention protocol starts) and at post-test (the day after the intervention protocol finishes).', 'description': 'Complete cognitive evaluation based on Cognitive Assessment Battery (CogniFit Inc., San Francisco, USA).'}, {'measure': 'Quality of Life Assessment', 'timeFrame': 'In Phase II, at pre-test (the day before the intervention protocol starts) and at post-test (the day after the intervention protocol finishes).', 'description': 'Short version of the self-perceived global physical and mental health scale from the Patient-Reported Outcomes Measurement Information System (PROMIS v.1.2).'}, {'measure': 'Paper-and-pencil Cognitive Assessment', 'timeFrame': 'In Phase II, at pre-test (the day before the intervention protocol starts) and at post-test (the day after the intervention protocol finishes).', 'description': 'The Montreal Cognitive Assessment (MoCA).'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['post-acute sequelae of COVID-19', 'PASC', 'cognitive dysfunction', 'computerized cognitive training', 'brain training'], 'conditions': ['Post-Acute COVID-19', 'Post Acute COVID-19 Syndrome', 'Cognitive Dysfunction', 'Cognitive Impairment']}, 'descriptionModule': {'briefSummary': 'The goal of this Phase I/II clinical trial is to assess the safety and maximum tolerated training time of a self-administered computerized cognitive training (CCT) in individuals with cognitive dysfunction as a consequence of COVID-19 infection.', 'detailedDescription': 'A Phase I/II protocol is designed to determine the safety of a Computerized Cognitive Training (CCT) aimed at ameliorating the cognitive dysfunction often observed in persons with post-acute sequelae of COVID-19 (PASC). The Phase I/II trial also aims at establishing the maximum tolerated training time per session of the CCT and to explore the feasibility of such intervention. In Phase I, through a 3+3 design, a dose-escalation trial will be set. Participants will be tested across subsequent training blocks of 15 minutes each, reporting on the experienced fatigue or adverse effects after every block. The safe training dose will be set to a block before extreme fatigue or a notable adverse effect has been reported by two or more participants. Once a safety training time has been established, a group of participants will engage in a 15-day training effectiveness assessment. After an initial thorough pre-test assessment, the intervention protocol will start. An evaluation day and a training day will be interspersed so that participants will complete a total of 8 training sessions (days 1, 3, 5, 7, 9, 11, 13 and 15). After the final day of intervention, a post-test assessment session will be carried out.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '25 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Adults between 25 and 55 years old.\n* History of infection with COVID-19 at least 3 months prior to expression of interest with a valid diagnostic or antibody test.\n* Presence of self-perceived cognitive dysfunction associated with post-acute sequelae of COVID-19 (concentration problems or brain fog).\n\nExclusion Criteria:\n\n* Suicidal traits.\n* Poor digital skills.\n* Not having access to a mobile phone or tablet with Internet connection during the time of the intervention (only for Phase II).\n* Not having 60 spare minutes per day to complete the intervention (only for Phase II).'}, 'identificationModule': {'nctId': 'NCT05582603', 'acronym': 'CCTLongCOVID', 'briefTitle': 'Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19', 'organization': {'class': 'OTHER', 'fullName': 'Universidad Antonio de Nebrija'}, 'officialTitle': 'Detailed Study on the Safety, Dosage and Feasibility of an Intervention Based on a Computerized Cognitive Training (CCT) for Individuals With Post-acute Sequelae of COVID-19 (PASC): A Phase I/II Trial', 'orgStudyIdInfo': {'id': 'UNNE-2021-010'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Computerized Cognitive Training', 'description': 'Individuals enrolled in Phase I and II will complete a Computerized Cognitive Training (CCT) based on an intervention with 15 different cognitive tasks in the form of games aimed at enhancing memory, attention, reasoning, perception and coordination skills. The CCT will be implemented in an app designed by CogniFit (CogniFit Inc., San Francisco, USA) to be used in tablets or mobile phones.', 'interventionNames': ['Behavioral: CCT Long COVID']}], 'interventions': [{'name': 'CCT Long COVID', 'type': 'BEHAVIORAL', 'otherNames': ['CogniFit CCT Long COVID'], 'description': "A 15-day training protocol in which every 48 hours participants' complete a series of different cognitive tasks in the form of games selected among a pool of 12 games from CogniFit (CogniFit Inc., San Francisco, USA) whose difficulty level is tailored to each individual by the a patented Individualized Training System™ (ITS) software that automatically chooses the activities and difficulty levels for each person in every session.", 'armGroupLabels': ['Computerized Cognitive Training']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Madrid', 'country': 'Spain', 'facility': 'Universidad Nebrija', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}], 'centralContacts': [{'name': 'Jon Andoni Duñabeitia, PhD', 'role': 'CONTACT', 'email': 'jdunabeitia@nebrija.es', 'phone': '0034 900321322'}, {'name': 'David Asensio', 'role': 'CONTACT', 'email': 'dasensiob@alumnos.nebrija.es'}], 'overallOfficials': [{'name': 'Jon Andoni Duñabeitia, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Universidad Nebrija'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Universidad Antonio de Nebrija', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Director of Research Center', 'investigatorFullName': 'Jon Andoni Duñabeitia', 'investigatorAffiliation': 'Universidad Antonio de Nebrija'}}}}